INO
Inovio Pharmaceuticals, Inc.
There isn't enough reported data to score INO yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
INO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Unavailable |
INO's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
INO PE Valuation
INO has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
INO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect INO's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
INO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.67 | +$1.88 |
| Q2 2026 | -$1.04 | +$1.53 |
| Q1 2026 | -$1.58 | +$1.57 |
| Q4 2025 | -$1.81 | +$2.14 |
| Q3 2025 | -$2.55 | +$1.89 |
| Q2 2025 | -$2.57 | +$2.54 |
| Q1 2025 | -$3.15 | +$2.33 |
| Q4 2024 | -$3.95 | +$2.14 |
INO is still losing money, but far less than before: $0.67 per share over the past year, against $20.64 at its worst in mid-2020.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over INO on earnings quality, reporting a profit while its opponent remains loss making.
INO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $117K | +14% |
| Q2 2024 | $100.8K | -55% |
| Q4 2023 | $102.7K | -18% |
| Q3 2023 | $388.4K | -96% |
| Q2 2023 | $226K | -71% |
| Q1 2023 | $114.9K | -42% |
| Q4 2022 | $124.7K | -85% |
| Q3 2022 | $9.2M | +3038% |
INO's revenue is growing: $298,901 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -6532% | N/A |
| Q1 2025 | -38337% | N/A |
| Q4 2024 | -17411% | +9276 points |
| Q2 2024 | -32946% | -16554 points |
| Q4 2023 | -26686% | +18191 points |
| Q3 2023 | -9153% | -8762 points |
| Q2 2023 | -16392% | -3116 points |
| Q1 2023 | -38238% | -2205 points |
INO's operating margin was −6532% last quarter, up 20154 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over INO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over INO on profitability, with a higher operating margin.
INO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.3M | +$6.4M |
| Q2 2026 | -$18M | +$2.8M |
| Q1 2026 | -$21.6M | +$5.3M |
| Q4 2025 | -$19.5M | +$165.9K |
| Q3 2025 | -$21.6M | +$5.8M |
| Q2 2025 | -$20.8M | +$7.8M |
| Q1 2025 | -$26.9M | +$1.9M |
| Q4 2024 | -$19.7M | +$6.6M |
INO has burned cash in almost every quarter: −$74M over the past year, against −$89M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over INO on cash generation, producing positive trailing cash flow while its opponent burns cash.
INO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +21% | +17M shares |
| 1 year | +154% | +59.8M shares |
| 3 years | +358% | +77.1M shares |
| 5 years | +485% | +81.8M shares |
INO has 99M diluted shares, up 154% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over INO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
INO Net Leverage
INO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
INO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.5 | Neutral |
| Stochastic | 32.9 | Neutral |
INO's weekly RSI is 57 (neutral) and its Stochastic is 33 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
INO PE vs Healthcare Sector
INO has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
INO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.08 | 35% above |
| 20 week MA | $1.10 | 33% above |
| 50 week MA | $1.35 | 8.1% above |
| 100 week MA | $1.67 | 13% below |
| 200 week MA | $4.98 | 71% below |
INO has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 71% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over INO on trend strength, trading above more of its moving averages.
INO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.1 | $123.1 | +207% |
| 2021 | $123.1 | $73.0 | -41% |
| 2022 | $73.0 | $18.4 | -75% |
| 2023 | $18.4 | $6.12 | -67% |
| 2024 | $6.12 | $1.87 | -69% |
| 2025 | $1.87 | $2.29 | +22% |
| 2026 YTD | $2.29 | $1.46 | -36% |
INO's yearly returns have swung widely, from +207% in 2020 to −75% in 2022. It's down 36% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over INO on returns for 2026, with the stronger performance.